Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | May 24, 2018 at 10:20 AM EDT

Why Melinta Therapeutics Shares Are Getting Crushed

Melinta Therapeutics saw its shares plunge on Thursday after the firm announced that it had priced a secondary offering.

Chris Lange | May 23, 2018 at 10:50 AM EDT

Why Cara Therapeutics Shares Are Soaring

Cara Therapeutics shares made a solid gain on Wednesday after the firm announced that it has licensed rights to commercialize…

Chris Lange | May 23, 2018 at 10:10 AM EDT

Esperion Therapeutics Shares Briefly Halted on Late-Stage Cholesterol Trial

Esperion Therapeutics shares were halted in premarket trading on Wednesday after the firm announced late-stage trial results for its cholesterol…

Chris Lange | May 22, 2018 at 11:40 AM EDT

Amgen Wins Another FDA Approval

Amgen shares made a slight gain on Tuesday after it was announced that the FDA approved its treatment of glucocorticoid-induced…

Chris Lange | May 21, 2018 at 12:30 PM EDT

Dova Pharmaceuticals Slumps Despite FDA Approval

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) shares dropped on Monday following a critical update from the U.S. Food and Drug Administration…

Chris Lange | May 21, 2018 at 10:10 AM EDT

Should Nabriva Be Seeing a Better Response for This Positive Trial?

Nabriva Therapeutics watched its shares take a step back on Monday's despite seeing positive results in its late-stage pneumonia trial.

Chris Lange | May 19, 2018 at 8:25 AM EDT

9 Companies Bracing for Big ASCO Reactions

This year marks the 54th annual meeting of the American Society of Clinical Oncology, the world’s largest clinical cancer conference.

Paul Ausick | May 18, 2018 at 9:45 AM EDT

FDA Lists Brand-Name Drugmakers That Obstruct Generic Development

The U.S. Food and Drug Administration on Thursday published a list of brand-name drug companies that the agency has received…

Trey Thoelcke | May 18, 2018 at 8:00 AM EDT

Amgen’s Novel Migraine Treatment Gets Key Approval

Amgen shares saw a nice bump after the FDA on Thursday approved its preventive treatment of migraine in adults.

Chris Lange | May 17, 2018 at 10:25 AM EDT

Why Jounce Shares Are Crumbling Ahead of ASCO

Jounce Therapeutics watched its shares crumble on Thursday after the firm released data from its midstage cancer trial.

Chris Lange | May 16, 2018 at 12:25 PM EDT

Why Evolus Shares Are Getting Slammed

Evolus watched its shares come crashing down on Wednesday after the company announced that the FDA issued a Complete Response…

Chris Lange | May 16, 2018 at 9:50 AM EDT

Are Abaxis Shareholders Getting Enough in the Buyout?

Abaxis shares hit an all-time high early on Wednesday after it was announced that Zoetis would be acquiring the firm.

Chris Lange | May 15, 2018 at 10:10 AM EDT

Are Xenon Pharmaceuticals Shares Making a Run?

Xenon Pharmaceuticals shares saw a handy gain on Tuesday after the firm announced positive data from a couple of its…

Lee Jackson | May 14, 2018 at 9:55 AM EDT

UBS Makes Big Health Care Swap in Top Performing Q-GARP Portfolio

Managers of the UBS Q-GARP portfolio continue searching for high-quality U.S. growth companies that are trading at attractive valuations. They…

Douglas A. McIntyre | May 12, 2018 at 8:15 AM EDT

Can the Mayo Clinic Teach Trump Anger Management and Create a New Industry?

President Trump gets mad at many people and reportedly has a foul temper. The Mayo Clinic advises those who are…

1 … 132 133 134 135 136 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Melinta Therapeutics Shares Are Getting Crushed

Why Cara Therapeutics Shares Are Soaring

Esperion Therapeutics Shares Briefly Halted on Late-Stage Cholesterol Trial

Amgen Wins Another FDA Approval

Dova Pharmaceuticals Slumps Despite FDA Approval

Should Nabriva Be Seeing a Better Response for This Positive Trial?

9 Companies Bracing for Big ASCO Reactions

FDA Lists Brand-Name Drugmakers That Obstruct Generic Development

Amgen’s Novel Migraine Treatment Gets Key Approval

Why Jounce Shares Are Crumbling Ahead of ASCO

Why Evolus Shares Are Getting Slammed

Are Abaxis Shareholders Getting Enough in the Buyout?

Are Xenon Pharmaceuticals Shares Making a Run?

UBS Makes Big Health Care Swap in Top Performing Q-GARP Portfolio

Can the Mayo Clinic Teach Trump Anger Management and Create a New Industry?

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Why Melinta Therapeutics Shares Are Getting Crushed

Why Cara Therapeutics Shares Are Soaring

Esperion Therapeutics Shares Briefly Halted on Late-Stage Cholesterol Trial

Amgen Wins Another FDA Approval

Dova Pharmaceuticals Slumps Despite FDA Approval

Should Nabriva Be Seeing a Better Response for This Positive Trial?

9 Companies Bracing for Big ASCO Reactions

FDA Lists Brand-Name Drugmakers That Obstruct Generic Development

Amgen’s Novel Migraine Treatment Gets Key Approval

Why Jounce Shares Are Crumbling Ahead of ASCO

Why Evolus Shares Are Getting Slammed

Are Abaxis Shareholders Getting Enough in the Buyout?

Are Xenon Pharmaceuticals Shares Making a Run?

UBS Makes Big Health Care Swap in Top Performing Q-GARP Portfolio

Can the Mayo Clinic Teach Trump Anger Management and Create a New Industry?

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how